PortalPublikationenIndicators of homologous recombination deficiency in breast ...

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

Standard

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. / Lips, E H; Mulder, L; Hannemann, Juliane; Laddach, N; Vrancken Peeters, M T F D; van de Vijver, M J; Wesseling, J; Nederlof, P M; Rodenhuis, S.

in: ANN ONCOL, Jahrgang 22, Nr. 4, 4, 2011, S. 870-876.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lips, EH, Mulder, L, Hannemann, J, Laddach, N, Vrancken Peeters, MTFD, van de Vijver, MJ, Wesseling, J, Nederlof, PM & Rodenhuis, S 2011, 'Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.', ANN ONCOL, Jg. 22, Nr. 4, 4, S. 870-876. <http://www.ncbi.nlm.nih.gov/pubmed/20937646?dopt=Citation>

APA

Lips, E. H., Mulder, L., Hannemann, J., Laddach, N., Vrancken Peeters, M. T. F. D., van de Vijver, M. J., Wesseling, J., Nederlof, P. M., & Rodenhuis, S. (2011). Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. ANN ONCOL, 22(4), 870-876. [4]. http://www.ncbi.nlm.nih.gov/pubmed/20937646?dopt=Citation

Vancouver

Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MTFD, van de Vijver MJ et al. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. ANN ONCOL. 2011;22(4):870-876. 4.

Bibtex

@article{6591d2163f6a47549445943599210628,
title = "Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.",
abstract = "Tumors with homologous recombination deficiency (HRD), such as BRCA1-associated breast cancers, are not able to reliably repair DNA double-strand breaks (DSBs) and are therefore highly sensitive to both DSB-inducing chemotherapy and poly (ADP-ribose) polymerase inhibitors. We have studied markers that may indicate the presence of HRD in HER2-negative breast cancers and related them to neoadjuvant chemotherapy response.",
author = "Lips, {E H} and L Mulder and Juliane Hannemann and N Laddach and {Vrancken Peeters}, {M T F D} and {van de Vijver}, {M J} and J Wesseling and Nederlof, {P M} and S Rodenhuis",
year = "2011",
language = "English",
volume = "22",
pages = "870--876",
journal = "ANN ONCOL",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

AU - Lips, E H

AU - Mulder, L

AU - Hannemann, Juliane

AU - Laddach, N

AU - Vrancken Peeters, M T F D

AU - van de Vijver, M J

AU - Wesseling, J

AU - Nederlof, P M

AU - Rodenhuis, S

PY - 2011

Y1 - 2011

N2 - Tumors with homologous recombination deficiency (HRD), such as BRCA1-associated breast cancers, are not able to reliably repair DNA double-strand breaks (DSBs) and are therefore highly sensitive to both DSB-inducing chemotherapy and poly (ADP-ribose) polymerase inhibitors. We have studied markers that may indicate the presence of HRD in HER2-negative breast cancers and related them to neoadjuvant chemotherapy response.

AB - Tumors with homologous recombination deficiency (HRD), such as BRCA1-associated breast cancers, are not able to reliably repair DNA double-strand breaks (DSBs) and are therefore highly sensitive to both DSB-inducing chemotherapy and poly (ADP-ribose) polymerase inhibitors. We have studied markers that may indicate the presence of HRD in HER2-negative breast cancers and related them to neoadjuvant chemotherapy response.

M3 - SCORING: Journal article

VL - 22

SP - 870

EP - 876

JO - ANN ONCOL

JF - ANN ONCOL

SN - 0923-7534

IS - 4

M1 - 4

ER -